The present invention relates to immediate release drug formulations, it includes dapagliflozin propylene glycol hydrates and pharmaceutically acceptable carrier, wherein the dapagliflozin propylene glycol hydrate preparation is the form selected from tablet, feed particles and capsule, wherein the dapagliflozin propylene glycol hydrate is to provide about 0.The amount of daily dose within the scope of 1~about 750mg/ days exists, and the daily dose is single dose or divided dose or multi-dose, gives for 1-4 times. The progress or breaking-out of related disease or illness with SGLT2 activity can be treated with what or be delayed to the immediate release drug formulations.本發明涉及速釋藥物製劑，其包含達格列嗪丙二醇水合物和藥學上可接受的載體，其中所述達格列嗪丙二醇水合物製劑爲選自片劑、原料顆粒和膠囊的形式，其中所述達格列嗪丙二醇水合物以提供約0.1～約750mg/天範圍內的日劑量的量存在，所述日劑量爲單劑量或分劑量或多劑量，1-4次給予。所述速釋藥物製劑可用於治療或延緩與SGLT2活性有關的疾病或病症的進展或發作。
